Synakis

Seed
synakis.ca Biotech & Healthcare Toronto, Canada
Total Funding $1.8M
Latest Round Undisclosed Seed
Last Announced May 11, 2026
Investors Undisclosed
Decision Makers 2 Verified

About Synakis

Synakis has created a vitreous substitute to transform the treatment of retinal detachment which use vitreous substitutes.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Seed
Global Headquarters Toronto, Canada
Tracked Since Oct 2, 2026

Web & Domain Identity

Official Website synakis.ca
Domain Registered Date Dec 3, 2021

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Seed announced

  2. Milestone

    Website domain registered

    synakis.ca

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Synakis.

Funding History

2 Rounds
Seed · May 11, 2026
Undisclosed
Pre-Seed · Undisclosed
$1,824,602 synakis.ca

Founders & Leadership

1

Alexander Baker

Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts